A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
Study identifier:D3562C00076
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment with Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography who have Coronary Artery Disease
Medical condition
Coronary Arteriosclerosis
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin calcium
Sex
All
Actual Enrollment
450
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2002
Primary Completion Date: 01 Nov 2005
Study Completion Date: 01 Nov 2005
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Contact Backup
AstraZeneca Medical Information (outside US)
-
-
Investigators
Principal Investigator
AstraZeneca Crestor Medical Sciences Director
AstraZeneca
